市場調查報告書
商品編碼
1510695
2030 年亞太地區心臟移植市場預測 - 區域分析 - 按手術類型、類型和最終用戶Asia Pacific Heart Transplant Market Forecast to 2030 - Regional Analysis - by Surgery Type, Type, and End User |
亞太心臟移植市場預計將從2022年的34.2568億美元成長到2030年的77.3974億美元。
不斷成長的老年人口推動亞太心臟移植市場
老年人群容易罹患心血管疾病、骨科疾病、代謝失調和神經系統疾病等。據世界衛生組織稱,到2050年,全球老齡化人口可能從2019年的約10億增至約21億。 中國和印度的人口均超過10億,截至2020年,亞洲人口將超過45億,佔世界總人口的一半以上。亞裔人口預計為 4.14 億,比 65 歲及以上的美國人 3.314 億多出約 20%。到2050年,預計亞洲老年人口將超過9.23億。因此,老年人口的成長以及心臟衰竭盛行率的增加推動了心臟移植市場的成長。
亞太心臟移植市場概況
亞太地區心臟移植市場分為中國、印度、日本、韓國、澳洲和亞太地區其他地區。預計亞太地區在預測期內將成為全球市場中複合年成長率最快的地區。該地區市場的成長歸因於醫療保健對器官捐贈重要性認知的提高以及社交媒體行銷的激增,以鼓勵對器官捐贈的積極態度。此外,在預測期內,改善醫療基礎設施和增加投資以提高製造能力預計將推動亞太地區心臟移植市場的發展。根據《BioMed Central》發表的一篇文章,中國 40% 以上的死亡歸因於心血管疾病。此外,2019年,我國心血管疾病患者約1,2,033萬人。快速的社會經濟進步正在影響中國人口的生活方式,這反過來又增加了心血管疾病、心臟或血管疾病的機會,可能導致心臟衰竭。目前,心臟移植是治療晚期心臟衰竭唯一眾所周知的有效方法。然而,由於心臟捐贈者數量有限,中國每年僅進行約300例心臟移植手術。因此,由於心臟移植等待時間較長,患有心臟衰竭的人選擇人工心臟移植。
亞太心臟移植市場收入及 2030 年預測(百萬美元)
亞太心臟移植市場細分
亞太地區心臟移植市場按手術類型、類型、最終用戶和國家進行細分。
根據手術類型,亞太心臟移植市場分為原位心臟移植和異位心臟移植。 2022年,原位心臟移植細分市場在亞太心臟移植市場中佔據更大佔有率。
從類型來看,亞太心臟移植市場分為活體捐贈心臟和人工心臟。 2022年,供體活體心臟細分市場在亞太心臟移植市場中佔據較大佔有率。
根據最終用戶,亞太心臟移植市場分為醫院、心臟中心等。 2022年,醫院細分市場在亞太心臟移植市場中佔據最大佔有率。
依國家/地區分類,亞太地區心臟移植市場分為中國、印度、韓國、日本、澳洲和亞太地區其他地區。 2022年,中國將主導亞太心臟移植市場。
Terumo Corp、Abbott Laboratories、SynCardia Systems LLC、BiVACOR Inc、BioVentrix Inc 和 LivaNova Plc 是亞太心臟移植市場上的一些領先公司。
表中的內容
The Asia Pacific heart transplant market is expected to grow from US$ 3,425.68 million in 2022 to US$ 7,739.74 million by 2030. It is estimated to grow at a CAGR of 10.7% from 2022 to 2030.
Growing Geriatric Population Boosts Asia Pacific Heart Transplant Market
The geriatric population is prone to CVDs, orthopedic disorders, metabolic disorders, and neurological disorders, among others. According to the WHO, the aging population across the world is likely to rise from ~1 billion in 2019 to ~2.1 billion by 2050. With China and India accounting for more than one billion people each, Asia's population surpassed 4.5 billion as of 2020, making up more than half of the world's total population. Asians were predicted to number 414 million, which is around 20% more than the 331.4 million Americans who are 65 years of age or older. By 2050, it is expected that Asia will have over 923 million elderly population. Hence, the growing elderly population, along with the increasing prevalence of heart failure, fuels the heart transplant market growth.
Asia Pacific Heart Transplant Market Overview
The Asia Pacific heart transplant market is segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. Asia Pacific is expected to register the fastest CAGR in the global market during the forecast period. The market growth in this region is ascribed to the rise in healthcare awareness of the importance of organ donation and a surge in social media marketing to encourage a positive attitude toward organ donation. Additionally, advancing healthcare infrastructure and increasing investments to boost manufacturing capacities are projected to drive the Asia Pacific heart transplant market during the forecast period. According to an article published in BioMed Central, more than 40% of the deaths in China are attributed to CVDs. In addition, in 2019, about 120.33 million people suffered from CVDs in China. Rapid socioeconomic progress is impacting the lifestyle of the population in China, which, in turn, increases the chances of contracting CVDs, conditions of heart or blood vessels that may result in heart failure. At present, heart transplantation is the only well-known effective treatment for advanced heart failure. However, owing to the limited number of heart donors, only ~300 heart transplants are performed in China annually. Therefore, people suffering from heart failure opt for artificial heart transplants due to the long waiting list for heart transplantation.
Asia Pacific Heart Transplant Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Heart Transplant Market Segmentation
The Asia Pacific heart transplant market is segmented into surgery type, type, end user, and country.
Based on surgery type, the Asia Pacific heart transplant market is bifurcated into orthotopic heart transplantation and heterotopic heart transplantation. The orthotopic heart transplantation segment held a larger share of the Asia Pacific heart transplant market in 2022.
In terms of type, the Asia Pacific heart transplant market is bifurcated into donor live heart and artificial heart. The donor live heart segment held a larger share of the Asia Pacific heart transplant market in 2022. Further, artificial heart segment is categorized into ventricular assisted device and total artificial heart.
Based on end user, the Asia Pacific heart transplant market is segmented into hospitals, cardiac centres, and others. The hospitals segment held the largest share of the Asia Pacific heart transplant market in 2022.
Based on country, the Asia Pacific heart transplant market is segmented into China, India, South Korea, Japan, Australia, and the Rest of Asia Pacific. China dominated the Asia Pacific heart transplant market in 2022.
Terumo Corp, Abbott Laboratories, SynCardia Systems LLC, BiVACOR Inc, BioVentrix Inc, and LivaNova Plc are some of the leading companies operating in the Asia Pacific heart transplant market.
Table of Content